FONR · Fonar Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '25 | Q2 '25 | Q3 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.47M | $25.55M | $26.04M | $24.95M | $27.16M | $25.39M | $25.72M | $25.84M | $24.26M | $25.42M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $424.0K | $455.0K | $440.0K | $376.0K | $441.0K | $416.0K | $414.0K | $467.0K | $342.0K | $435.0K |
| SG&A | $8.37M | $6.24M | $6.81M | $6.93M | $7.99M | $5.59M | $7.59M | $4.87M | $6.60M | $7.14M |
| Total Operating Expenses | $24.03M | $22.55M | $22.85M | $22.52M | $23.50M | $20.50M | $21.97M | $19.27M | $20.02M | $21.25M |
| D&A | - | - | $1.06M | $1.24M | $1.24M | $1.22M | $1.13M | $1.20M | $1.10M | $1.14M |
| Operating Income | $2.82M | $3.44M | $3.68M | $2.97M | $4.13M | $5.99M | $4.33M | $7.03M | $4.28M | $4.50M |
| Interest Expense | $3.0K | $4.0K | $1.0K | $6.0K | $9.0K | $10.0K | $9.0K | $14.0K | - | - |
| Income Tax | $492.0K | $903.0K | $1.01M | $762.0K | $1.01M | $1.37M | $1.85M | $1.67M | $1.46M | $17.0K |
| Net Income | $1.64M | $2.06M | $2.26M | $1.96M | $2.51M | $3.76M | $1.87M | $4.11M | $2.23M | $3.86M |
| EPS - Basic | - | - | - | - | - | - | - | - | $0.32 | $0.56 |
| EPS - Diluted | - | - | - | - | - | - | - | - | $0.32 | $0.55 |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '25 | Q2 '25 | Q3 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53.65M | $52.98M | $54.28M | $56.33M | $54.26M | $56.34M | $53.98M | $51.69M | $51.28M | $49.64M |
| Accounts Receivable | - | $4.75M | $5.15M | $5.30M | - | $4.04M | - | - | $3.86M | - |
| Inventory | $2.83M | - | - | $2.81M | $2.71M | $2.72M | - | - | $2.57M | - |
| Accounts Payable | $2.29M | $1.91M | $2.52M | $1.30M | $1.23M | $1.86M | $1.68M | $1.04M | $1.58M | $1.72M |
| Current Assets | $148.01M | $143.71M | $143.74M | $144.67M | $141.10M | $140.32M | $135.83M | $129.15M | $125.66M | $122.00M |
| Total Assets | $219.22M | $217.22M | $218.35M | $216.91M | $214.92M | $214.25M | $209.63M | $201.56M | $200.58M | $199.34M |
| Current Liabilities | $16.12M | $14.37M | $16.66M | $17.12M | $14.04M | $17.86M | $14.50M | $14.23M | $15.62M | $13.93M |
| Long-term Debt | - | - | $40.0K | $7.0K | - | $66.9K | $80.0K | $115.0K | $158.8K | $126.0K |
| Total Liabilities | $54.77M | $54.36M | $56.96M | $56.80M | $54.66M | $57.46M | $52.60M | $47.48M | $49.75M | $48.72M |
| Stockholders' Equity | $178.57M | $176.93M | $174.87M | $172.61M | $171.88M | $165.97M | $165.76M | $161.30M | $157.91M | $157.18M |
| Retained Earnings | $672.0K | ($969.0K) | ($3.02M) | ($5.29M) | ($6.02M) | ($13.62M) | ($14.45M) | ($20.09M) | ($24.19M) | ($25.43M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '25 | Q2 '25 | Q3 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $1.69M | - | - | - | - | $2.62M | - | - |
| Investing Cash Flow | - | - | ($2.37M) | - | - | - | - | ($79.0K) | - | - |
| Financing Cash Flow | - | - | ($1.38M) | - | - | - | - | ($2.13M) | - | - |
| CapEx | - | - | $1.87M | $754.0K | $598.0K | $133.0K | $187.0K | $63.0K | - | - |
| Free Cash Flow | - | - | ($177.0K) | - | - | - | - | $2.56M | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '25 | Q2 '25 | Q3 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 10.7% | 13.5% | 14.1% | 11.9% | 15.2% | 23.6% | 16.8% | 27.2% | 17.6% | 17.7% |
| EBITDA margin | - | - | 18.2% | 16.8% | 19.8% | 28.4% | 21.2% | 31.8% | 22.2% | 22.2% |
| Net margin | 6.2% | 8.0% | 8.7% | 7.9% | 9.2% | 14.8% | 7.3% | 15.9% | 9.2% | 15.2% |
| Free cash flow margin | - | - | -0.7% | - | - | - | - | 9.9% | - | - |
| FCF / Net income | - | - | -0.08 | - | - | - | - | 0.62 | - | - |
| R&D / Revenue | 1.6% | 1.8% | 1.7% | 1.5% | 1.6% | 1.6% | 1.6% | 1.8% | 1.4% | 1.7% |
| SG&A / Revenue | 31.6% | 24.4% | 26.2% | 27.8% | 29.4% | 22.0% | 29.5% | 18.8% | 27.2% | 28.1% |
| Effective tax rate | 23.1% | 30.5% | 30.9% | 28.0% | 28.6% | 26.7% | 49.7% | 28.9% | 39.6% | 0.4% |
| Return on assets | 0.7% | 0.9% | 1.0% | 0.9% | 1.2% | 1.8% | 0.9% | 2.0% | 1.1% | 1.9% |
| Return on equity | 0.9% | 1.2% | 1.3% | 1.1% | 1.5% | 2.3% | 1.1% | 2.5% | 1.4% | 2.5% |
| Return on invested capital | - | - | 1.5% | 1.2% | - | 2.6% | 1.3% | 3.1% | 1.6% | 2.8% |
| Liquidity | ||||||||||
| Current ratio | 9.18 | 10.00 | 8.62 | 8.45 | 10.05 | 7.86 | 9.37 | 9.07 | 8.04 | 8.76 |
| Quick ratio | 9.00 | 10.00 | 8.62 | 8.28 | 9.86 | 7.71 | 9.37 | 9.07 | 7.88 | 8.76 |
| Cash ratio | 3.33 | 3.69 | 3.26 | 3.29 | 3.86 | 3.16 | 3.72 | 3.63 | 3.28 | 3.56 |
| Leverage | ||||||||||
| Debt / Equity | - | - | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / Assets | - | - | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | - | - | 0.01 | 0.00 | - | 0.01 | 0.01 | 0.01 | 0.03 | 0.02 |
| Interest coverage | 940.0x | 860.5x | 3682.0x | 494.5x | 458.9x | 598.6x | 481.2x | 502.1x | - | - |
| Equity multiplier | 1.23 | 1.23 | 1.25 | 1.26 | 1.25 | 1.29 | 1.26 | 1.25 | 1.27 | 1.27 |
| Liabilities / Assets | 0.25 | 0.25 | 0.26 | 0.26 | 0.25 | 0.27 | 0.25 | 0.24 | 0.25 | 0.24 |
| Efficiency | ||||||||||
| Asset turnover | 0.12 | 0.12 | 0.12 | 0.12 | 0.13 | 0.12 | 0.12 | 0.13 | 0.12 | 0.13 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | 68d | 72d | 78d | - | 58d | - | - | 58d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | 53.4x | 29.5x |
| P / B | - | - | - | - | - | - | - | - | 0.7x | 0.7x |
| P / S | - | - | - | - | - | - | - | - | 4.7x | 4.2x |
| EV / EBITDA | - | - | - | - | - | - | - | - | 11.7x | 10.2x |
| Growth | ||||||||||
| Revenue growth (YoY) | -2.6% | 2.4% | 0.8% | -1.7% | 5.6% | 4.7% | 1.2% | 11.4% | -0.9% | 3.5% |
| Revenue CAGR (3y) | 1.4% | 1.7% | 3.1% | 0.6% | 3.4% | 6.3% | 3.7% | 7.2% | 4.2% | 5.4% |
| Revenue CAGR (5y) | 2.8% | 3.8% | 3.7% | 3.1% | 4.6% | 4.7% | 4.2% | 4.5% | 3.8% | 3.9% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -31.7% | 16.0% | -47.6% | -50.4% | -4.6% | 40.0% | -3.8% | 73.2% | -34.9% | -21.4% |
| Net income growth (YoY) | -34.5% | 4.7% | -44.9% | -47.8% | 33.9% | 68.4% | -51.5% | 100.6% | -44.5% | 68.5% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | -43.9% | 1.9% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | 45.3% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | -9.5% | - | - |
| Book value growth (YoY) | 3.9% | 2.5% | 8.4% | 4.0% | 3.7% | 5.1% | 5.5% | 6.0% | 5.1% | 6.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-06-30.
Product / service
$208.70M totalTotal$104.35M · 50.0%
Managementof Diagnostic Imaging Centers$95.37M · 45.7%
Manufacturingand Servicingof Medical Equipment$8.98M · 4.3%
Peer comparison
Same SIC group: Electromedical & Electrotherapeutic Apparatus
Comparing FONAR CORP against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Mar 18, 1999 | $0.1900 |
| Dec 16, 1998 | $0.1900 |
| Sep 15, 1998 | $0.1900 |
| May 13, 1998 | $0.5700 |